Specifically, the PSMA-targeted radioligand therapy (Pluvicto, Advanced Accelerator Applications USA, Inc, Millburn, New Jersey) is indicated for adults who have progressed after treatment with androgen receptor pathway inhibitors and taxane-based chemotherapy.

Multigene sequencing identifies patients with metastatic breast cancer who will benefit from targeted therapy, but its use must be driven by a framework of actionability, show data presented at the 2021 San Antonio Breast Cancer Symposium.

Testing for circulating tumor DNA accurately identifies patients with breast cancer suitable for mutation-targeted therapies, results of the phase 2a plasmaMATCH trial show.

Tejas Patil rounds up findings from the ALEX, ALTA-1L, ARROW, LIBRETTO-001, GEOMETEY mono-1 and VISION studies of non-small-cell lung cancer patients with ALK, RET, or MET alterations (9:56).

Phase I results reported at the AACR Annual Meeting 2019 in Atlanta, Georgia, USA, point to the potential of a chimeric antigen receptor T-cell therapy directed against mesothelin in patients with malignant pleural disease.

Targeted therapy improves survival over nontargeted therapy among patients with metastatic renal cell carcinoma, including those who are older and have disabilities, shows an analysis of real-world data.

The remaining patient experienced rapid clinical deterioration and was unable to receive targeted treatment.

Camidge DR et al.  Nat Rev Clin Oncol  2019; 16(6): 341-355. doi:10.1038/s41571-019-0173-9.

And of 42 patients who were treated with targeted therapy based on their plasma NGS result, 36 (85.7%) achieved disease control, with a complete response in one patient, a partial response in 19 patients and stable disease in 16.

Adding immune checkpoint inhibitors to targeted therapy or radiotherapy can worsen some of the toxic effects associated with these treatment modalities, indicate two reports published in JAMA Oncology .

This report provides an overview of three studies investigating the combination of immunotherapy with targeted agents in treatment-naïve patients with locally advanced or metastatic renal cell carcinoma.

Francolini and colleagues note that “the treatment of [metastatic] CRPC is a rapidly evolving landscape,” especially given the promising reports of first-line treatment with PARP inhibitors and the use of androgen receptor-targeted agents in the metastatic hormone-sensitive setting.

Participants had disease that was resistant or intolerant to at least one available standard therapy or disease for which an investigational clinical trial is considered standard of care.